Stephen M. Muniz

Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts.

Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Appeering, Inc. develops a web-based social application. The company was founded by Joshua Fertik and Oren Kagan in 2011 and is headquartered in Boston, MA.

Entrega, Inc. develops oral drug delivery technologies. The firm’s platform enables novel applications in a variety of fields, such as disease management and tracking in the burgeoning mobile health arena. Its proprietary technology seeks to solve the oral delivery problem with an engineering solution that protects the payload and delivers biological molecules, drug substances and nanoparticles. The company was founded by Samir Mitragotri in 2010 and is headquartered in Boston, MA.

Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy.

Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA.

Locke Lord LLP provides legal services. The private company is based in Houston, TX.